Bio
Has 30 years of experience in the healthcare sector, during which he has performed a broad spectrum of roles covering corporate strategy, operational management, business development and marketing. Before joining Abingworth in 2006, he was CEO and Co-Founder of Ionix Pharmaceuticals, which was divested to Vernalis in 2005. Prior to this he served as Chief Operating Officer of Signature BioScience, Hexagen and Cantab Pharmaceuticals. Andy has also held business development and marketing positions at Amersham, Celltech and Roche. His current directorships include NeurAxon, Novacta, Syntaxin and PBL Technology. At Abingworth, he helps to identify and create new businesses and provide strategic and operational support for portfolio companies. Andy has a BSc in Chemistry from University of East Anglia and a Diploma in Marketing from the Institute of Marketing.
Career
|
Abingworth LLPAn international investment group dedicated exclusively to the life sciences and healthcare sectors |